{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:59:53Z","timestamp":1790398793343,"version":"4.1.0"},"reference-count":19,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.5582\/ddt.2026.01033","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:11:17Z","timestamp":1787695877000},"page":"322-328","source":"Crossref","is-referenced-by-count":0,"title":["Simultaneous determination of belzutifan and cabozantinib, oral agents for renal cell carcinoma, in human plasma using high-performance liquid chromatography"],"prefix":"10.5582","volume":"20","author":[{"given":"Yoshito","family":"Gando","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacodynamics and Toxicology Analytics, Meiji Pharmaceutical University, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Yasu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacodynamics and Toxicology Analytics, Meiji Pharmaceutical University, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Choueiri TK, Powles T, Peltola K, <i>et al.<\/i> Belzutifan versus everolimus for advanced renal-cell carcinoma. N Engl J Med. 2024; 391:710-721.","DOI":"10.1056\/NEJMoa2313906"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Choueiri TK, Escudier B, Powles T, <i>et al.<\/i> Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373:1814-1823.","DOI":"10.1056\/NEJMoa1510016"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Marathe DD, Jauslin PM, Kleijn HJ, de Miranda Silva C, Chain A, Bateman T, Shaw PM, Abraham AK, Kauh EA, Liu Y, Perini RF, de Alwis DP, Jain L. Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling. CPT Pharmacometrics Syst Pharmacol. 2023; 12:1499-1510.","DOI":"10.1002\/psp4.13028"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Okano M, Ueda T, Nishitani Y, Kano H, Ikekita A, Kageyama S. UDP-glucuronosyltransferase 2B17 genotyping in Japanese athletes and evaluation of the current sports drug testing for detecting testosterone misuse. Drug Test Anal. 2013; 5:166-181.","DOI":"10.1002\/dta.1394"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit. 1998; 20:243-247.","DOI":"10.1097\/00007691-199806000-00001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Marathe DD, Jauslin PM, Jan Kleijn H, De Miranda Silva C, Chain A, Abraham AK, Kauh EA, Liu Y, Perini RF, Alwis DP, Jain L. Exposure-response analyses for belzutifan to inform dosing considerations and labeling. J Clin Pharmacol. 2024; 64:1246-1258.","DOI":"10.1002\/jcph.2459"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Cerbone L, Combarel D, Geraud A, <i>et al.<\/i> Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics\/pharmacodynamics study. ESMO Open. 2021; 6:100312.","DOI":"10.1016\/j.esmoop.2021.100312"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nokihara H, Nishio M, Yamamoto N, Fujiwara Y, Horinouchi H, Kanda S, Horiike A, Ohyanagi F, Yanagitani N, Nguyen L, Yaron Y, Borgman A, Tamura T. Phase 1 study of cabozantinib in Japanese patients with expansion cohorts in non-small-cell lung cancer. Clin Lung Cancer. 2019; 20:e317-e328.","DOI":"10.1016\/j.cllc.2018.12.018"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. G\u00e9raud A, Combarel D, Funck-Brentano C, Beaulieu Q, Zahr N, Broutin S, Spano JP, Massard C, Besse B, Gougis P. A score to predict the clinical usefulness of therapeutic drug monitoring: Application to oral molecular targeted therapies in cancer. Clin Pharmacol Ther. 2024; 116:678-689.","DOI":"10.1002\/cpt.3193"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Choueiri TK, McDermott DF, Merchan J, Bauer TM, Figlin R, Heath EI, Michaelson MD, Arrowsmith E, D&apos;Souza A, Zhao S, Roy A, Perini R, Vickery D, Tykodi SS. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol. 2023; 24:553-562.","DOI":"10.1016\/S1470-2045(23)00097-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kolli P, Galla R. Bioanalytically validated LC-UV method for estimation of hypoxia-inducible factor-2 alpha (HIF-2\u03b1) inhibitor in spiked human plasma. Curr Trends Biotechnol Pharm. 2025; 19:126-132.","DOI":"10.5530\/ctbp.2025.2s.12"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Maruyama S, Kato M, Hiraga T, Ishida M, Kanno H. Quantitative determination of plasma cabozantinib concentration using HPLC-UV and its application to patients with renal cell carcinoma. Biomed Chromatogr. 2023; 37:e5599.","DOI":"10.1002\/bmc.5599"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yasu T, Gando Y, Nishijima R, Ikuta R, Suzuki M, Shirota M. Plasma cabozantinib level measurement in patients with renal cell and hepatocellular carcinomas using a simple HPLC-UV method suitable for clinical application. Curr Oncol. 2023; 30:4871-4879.","DOI":"10.3390\/curroncol30050367"},{"key":"14","unstructured":"14. US DHHS, FDA, CDER, CVM. Guidance for Industry: Bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine, Rockville, MD, 2018."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Brown JR, Eichhorst B, Hillmen P, <i>et al.<\/i> Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023; 388:319-332.","DOI":"10.1056\/NEJMoa2211582"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nguyen L, Chapel S, Tran BD, Lacy S. Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma. J Pharmacokinet Pharmacodyn. 2019; 46:577-589.","DOI":"10.1007\/s10928-019-09659-y"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nguyen L, Holland J, Ramies D, Mamelok R, Benrimoh N, Ciric S, Marbury T, Preston RA, Heuman DM, Gavis E, Lacy S. Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib. J Clin Pharmacol. 2016; 56:1130-1140.","DOI":"10.1002\/jcph.714"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lyseng-Williamson KA. Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use. Drugs Ther Perspect. 2018; 34:457-465.","DOI":"10.1007\/s40267-018-0547-6"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tan Z, V\u00f6ller S, Yin A, Rieborn A, Gelderblom AJ, van der Hulle T, Knibbe CAJ, Moes DJAR. Population pharmacokinetics of cabozantinib in metastatic renal cell carcinoma patients: Towards drug expenses saving regimens. Clin Pharmacokinet. 2024; 63:857-869.","DOI":"10.1007\/s40262-024-01379-y"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/4\/20_2026.01033\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:29:52Z","timestamp":1790396992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/4\/20_2026.01033\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2026.01033","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"2026.01033"}}